http://www.empr.com/da-hee-han-pharmd/author/944/ Latest articles by Da Hee Han, PharmD from MPR MPR custserv@haymarketmedia.com no The immediate post-operative addition of clopidogrel to aspirin after coronary artery bypass grafting (CABG) proved to be safe and improved overall graft patency, according to data presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session. http://www.empr.com/aspirin-clopidogrel-post-cabg-improve-overall-bypass-graft-patency/article/283909/ Mon, 11 Mar 2013 19:50:25 GMT The immediate post-operative addition of clopidogrel to aspirin after coronary artery bypass grafting (CABG) proved to be safe and improved overall graft patency, according to data presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session. MPR Pitavastatin has beneficial effects on a marker of oxidative stress and pericellular MT1-MMP activity in hypercholesterolemic patients compared with eicosapentaenoic acid (EPA), according to a study at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session. http://www.empr.com/pitavastatin-more-beneficial-than-epa-in-decreasing-plaque-vulnerability/article/283896/ Mon, 11 Mar 2013 18:56:58 GMT Pitavastatin has beneficial effects on a marker of oxidative stress and pericellular MT1-MMP activity in hypercholesterolemic patients compared with eicosapentaenoic acid (EPA), according to a study at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session. MPR Pitavastatin is an acceptable alternative for patients who are intolerant to other statins, according to research presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session by Bobby Hollaway, CNA, from the Intermountain Medical Center, Murray, UT. http://www.empr.com/pitavastatin-effective-alternative-in-otherwise-statin-intolerant-patients/article/283895/ Mon, 11 Mar 2013 18:45:53 GMT Pitavastatin is an acceptable alternative for patients who are intolerant to other statins, according to research presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session by Bobby Hollaway, CNA, from the Intermountain Medical Center, Murray, UT. MPR At ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, researchers presented that in post-cardiac surgery patients, omega-3 fatty acids (PUFA) therapy significantly reduces the risk of developing atrial fibrillation. http://www.empr.com/omega-3-fatty-acid-reduces-risk-of-developing-atrial-fibrillation/article/283885/ Mon, 11 Mar 2013 17:38:27 GMT At ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, researchers presented that in post-cardiac surgery patients, omega-3 fatty acids (PUFA) therapy significantly reduces the risk of developing atrial fibrillation. MPR Srikanth Vallurupalli, MD, and colleagues from the University of Arkansas Medical Sciences, Little Rock, AR presented results at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, in support of intravenous (IV) magnesium significantly enhancing the efficacy of ibutilide in atrial fibrillation conversion and flutter. http://www.empr.com/iv-magnesium-enhances-ibutilide-in-atrial-fibrillationflutter-conversion/article/283760/ Sun, 10 Mar 2013 21:30:00 GMT Srikanth Vallurupalli, MD, and colleagues from the University of Arkansas Medical Sciences, Little Rock, AR presented results at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, in support of intravenous (IV) magnesium significantly enhancing the efficacy of ibutilide in atrial fibrillation conversion and flutter. MPR After reports of having met the primary endpoints in the ATLAS-ACS TIMI-52 study, rivaroxaban 2.5mg and 5mg demonstrated a benefit over placebo in terms of cardiac mortality and bleeding risk as presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session. http://www.empr.com/net-clinical-benefit-of-rivaroxaban-for-thrombosis-prevention-in-acs-patients/article/283757/ Sun, 10 Mar 2013 20:45:00 GMT After reports of having met the primary endpoints in the ATLAS-ACS TIMI-52 study, rivaroxaban 2.5mg and 5mg demonstrated a benefit over placebo in terms of cardiac mortality and bleeding risk as presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session. MPR At ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, Ramin Farzaneh-Far, MD, FACC, from Gilead Sciences, Foster City, CA, reported that the QTc interval shortening and anti-ischemic effect of ranolazine provide evidence of a similar mechanism of action, such as inhibition of late sodium current (INA,L). http://www.empr.com/linear-correlation-supports-common-mechanism-of-action-for-ranolazine/article/283755/ Sun, 10 Mar 2013 19:59:46 GMT At ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, Ramin Farzaneh-Far, MD, FACC, from Gilead Sciences, Foster City, CA, reported that the QTc interval shortening and anti-ischemic effect of ranolazine provide evidence of a similar mechanism of action, such as inhibition of late sodium current (INA,L). MPR A study of more than 4,000 patients found no clear association between calcium channel blocker (CCB) therapy and new-onset diabetes in an Asian population with cardiovascular disease, a study to explore this controversy concluded at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session. http://www.empr.com/no-association-between-ccbs-diabetes-mellitus-found-in-asian-patients-with-cvd/article/283752/ Sun, 10 Mar 2013 19:10:20 GMT A study of more than 4,000 patients found no clear association between calcium channel blocker (CCB) therapy and new-onset diabetes in an Asian population with cardiovascular disease, a study to explore this controversy concluded at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session. MPR Triflusal more effectively and consistently improved symptoms and blood flow in patients with primary vascular dysregulation (PVD) compared with acetylsalicylic acid (ASA) and should be considered a treatment option in this population, results of study presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session have found. http://www.empr.com/patients-with-primary-vascular-dysregulation-benefit-from-triflusal-vs-asa/article/283749/ Sun, 10 Mar 2013 18:43:48 GMT Triflusal more effectively and consistently improved symptoms and blood flow in patients with primary vascular dysregulation (PVD) compared with acetylsalicylic acid (ASA) and should be considered a treatment option in this population, results of study presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session have found. MPR At ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, study authors presented that carvedilol compared to metoprolol was associated with a significant reduction in heart failure hospitalizations, death, and ventricular arrhythmias. http://www.empr.com/carvedilol-superior-to-metoprolol-in-mortality-reductions-for-heart-failure/article/283747/ Sun, 10 Mar 2013 18:00:00 GMT At ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, study authors presented that carvedilol compared to metoprolol was associated with a significant reduction in heart failure hospitalizations, death, and ventricular arrhythmias. MPR